Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-11 | 2024-09 | -0.05 | N/A | N/A | N/A |
2024-08-12 | 2024-06 | -0.05 | -0.05 | N/A | N/A |
2024-05-13 | 2024-03 | -0.07 | -0.05 | 0.02 | 28.57% |
2024-04-01 | 2023-12 | -0.05 | -0.06 | -0.01 | -20.00% |
2023-11-13 | 2023-09 | 0 | -0.05 | N/A | N/A |
2023-08-14 | 2023-06 | 0 | -0.06 | N/A | N/A |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-09-07 | Cantor Fitzgerald | Upgrade | Overweight | |
2020-09-16 | Ascendiant Capital | Upgrade | Buy | |
2019-12-17 | Maxim Group | Upgrade | Hold | Buy |
2018-01-25 | Maxim Group | Upgrade | Buy | |
2013-10-06 | Sidoti & Co. | Downgrade | Buy | Neutral |
2013-04-14 | Sidoti & Co. | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2016-03-08 | CHEN SHU-CHIH | Director and Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
2013-05-14 | CROSS ALEXANDER DENNIS | Director | 0.00 | Purchase |
2024-04-09 | FINN JONATHAN F. | Director | 25.00K | Purchase |
2017-11-14 | GUSE KYLE | General Counsel | 10.00K | Purchase |
2016-03-08 | QUAY STEVEN C | Chief Executive Officer | 0.00 | Purchase |
2017-04-16 | REMMEL H LAWRENCE | Director | 3.13K | Purchase |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Group Inc | 5.68M | 7.15M | 4.51% |
2023-06-29 | Blackrock Inc. | 2.90M | 3.65M | 2.30% |
2023-06-29 | Laurion Capital Management, LP | 2.23M | 2.80M | 1.77% |
2023-06-29 | Geode Capital Management, LLC | 1.11M | 1.40M | 0.88% |
2023-06-29 | Renaissance Technologies, LLC | 1.07M | 1.35M | 0.85% |
2023-06-29 | State Street Corporation | 436.27K | 549.70K | 0.35% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.78M | 4.76M | 3.00% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.66M | 2.10M | 1.32% |
2023-05-30 | Fidelity Extended Market Index Fund | 659.95K | 613.75K | 0.52% |
2023-05-30 | BlackRock Advantage Small Cap Core Fund | 340.50K | 316.67K | 0.27% |
2023-05-30 | Fidelity Total Market Index Fund | 182.91K | 170.11K | 0.15% |
2023-05-30 | Fidelity Series Total Market Index Fund | 142.17K | 132.22K | 0.11% |
Split | Date |
---|---|
1 : 12 | 2018-04-20 |
1 : 15 | 2016-08-26 |
-
Don’t get too excited, about to be dragged down. 3.35 EOD
-
Nobody is “trapped”. Noobs throwing around lingo they heard somewhere. If you don’t actually know how the process works, just be quiet. Typing that crap let’s everyone know you have zero clue what you are doing.
-
Told y’all. Trash management is killing what promise this company has.
-
They are either massively incompetent or shady as hell, neither of which bode well for shareholders. Voted NO and not changing it.
-
When they have to stall to try to convince people to vote yes, after having already been rejected on their previous attempt to issue more shares, it screams INCOMPETENT MANAGEMENT! The Shareholders don’t want to line your pockets with 1 Billion dollars when you haven’t given them ANYTHING! You can’t even get an update on today’s process out correctly!
-
Ironic that once again shareholders are left in the dark, not a peep from management on the outcome.
-
So absentee votes automatically counted as a NO vote, so how again did they not have enough votes to complete the process? This is straight manipulation by extending it to try to get the desired outcome they want.
-
Simple communication from management would do wonders for this company. Instead they literally refuse to update on damn near everything. Glad I sold at $3.80 last week, I’ll consider buying back in when it goes under $2. Terrible tactics by management is killing the potential…
-
For the 2nd time, they didn’t get a YES vote because they aren’t giving shareholders enough reason to vote in favor of dilution. They refuse to give any updates of any significance to increase sentiment. Likely because they actually have none. Quay is distracted with making his Wuhan conspiracy speeches, the research has taken a back seat and it shows.
-
If y’all actually believe they didn’t have enough votes, then you’re gullible as hell.
-
This company is straight up shady as hell.
-
Translation = we realized we weren’t going to get the YES vote so we extended the voting timeline.
-
So now they are claiming not enough votes cast and extended to Oct 7th? Shady company here…
-
Telling y’all. $1.80 after they add those shares. Out at $3.85, will start adding after this clown show is over. Can easily double my shares for free.
-
$1.80 on Wednesday.
-
Shorts gonna drag this down, after the Yes vote on Tuesday it’ll be $2 or less.
-
You can believe in the product all you want, but a severe lack of leadership by Quay is severely hampering this process. No excuse for this clown show.
-
why was the update on Phase2? And why in Sweden?
-
Shorts piling in. They know it’s a huge payday when this drops to the $2 range after Tuesday. Gonna be a long struggle to climb back up.
-
Now you know why SABBY is in this.
-
Atos: contract to reinforce a supercomputer in Sweden
news.google.com • -
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen
globenewswire.com • -
3 Dirt-Cheap Drug Developers With Blockbuster Potential
investorplace.com • -
3 Penny Stock Moonshots with 300%+ Upside Potential by 2025
investorplace.com • -
Atossa Therapeutics names Heather Rees as CFO
proactiveinvestors.com • -
Atossa Therapeutics Appoints Heather Rees as Chief Financial Officer
globenewswire.com • -
Atossa Set to Join Russell 3000® Index Effective June 28, 2024
globenewswire.com • -
Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar
investorplace.com • -
Atossa to Present at the Sidoti Small-Cap Investor Conference
globenewswire.com •